大鼠肠缺血-再灌注损伤中FGFR2表达的规律

目的观察酸性成纤维细胞生长因子受体2（acid fibroblast growth factor receptor,FGFR2）在肠缺血-再灌注损伤中表达规律。方法以大鼠肠系膜上动脉（SMA）夹闭造成肠缺血-再灌注损伤模型,并将动物随机分为假手术组（C组）、生理盐水对照组（R组）、改构体aFGF治疗组（F组）。除假手术组外,其余各组动物均于缺血45min后于2、6、12、24h活杀,取小肠组织标本,免疫组化和RT—PCR检测FGFR的表达规律。结果在正常大鼠,FGFR分布在小肠绒毛上皮细胞的肠腔侧、侧壁和小肠隐窝朝向隐窝腔的-侧的细胞膜上。缺血和再灌注的初期,FGFR的表达未发生明显变化,随着再灌注时间的延长逐渐增强。FGF使FGFR的表达有明显的增强和提前表达。缺血和再灌注使FGFRmRNA的表达迅速增加,在再灌注后6h达到高峰。F组FGFRmRNA的表达较R组相应时间点显著增加（P〈0．05）。结论FGFR在肠缺血-再灌注损伤的修复中起积极作用。     

Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.

Key growth factor-receptor interactions involved in angiogenesis are possible targets for therapy of CNS tumors. Vascular endothelial growth factor (VEGF) is a highly specific endothelial cell mitogen that has been shown to stimulate angiogenesis, a requirement for solid tumor growth. The expression of VEGF, the closely related placental growth factor (PIGF), the newly cloned endothelial high affinity VEGF receptors KDR and FLT1, and the endothelial orphan receptors FLT4 and Tie were analyzed by in situ hybridization in normal human brain tissue and in the following CNS tumors: gliomas, grades II, III, IV; meningiomas, grades I and II; and melanoma metastases to the cerebrum. VEGF mRNA was up-regulated in the majority of low grade tumors studied and was highly expressed in cells of malignant gliomas. Significantly elevated levels of Tie, KDR, and FLT1 mRNAs, but not FLT4 mRNA, were observed in malignant tumor endothelia, as well as in endothelia of tissues directly adjacent to the tumor margin. In comparison, there was little or no receptor expression in normal brain vasculature. Our results are consistent with the hypothesis that these endothelial receptors are induced during tumor progression and may play a role in tumor angiogenesis.     

血管内皮生长因子受体在膀胱癌中的表达及临床意义

目的：探讨血管内皮生长因子受体在膀胱癌中的表达及与临床病理因素的相关性。方法：免疫组化法采用链霉菌抗生物素一过氧化物酶连接法(SP法)对50例膀胱癌标本，20例正常膀胱组织标本中血管内皮生长因子受体的表达进行检测。结果：血管内皮生长因子受体在大多数膀胱癌组织中表达(74％)，而且其表达水平与病理分期及组织分级呈正相关。在正常膀胱组织中无1例表达(0％)。结论：膀胱癌组织中血管内皮生长因子受体阳性表达，提示其在膀胱癌的血管生成中起着重要作用。     

Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury

Although hypoxia stimulates the expression of vascular endothelial growth factor (VEGF), little is known of the role or mechanism by which VEGF functions after ischemia and reperfusion (I/R) injury. In this report, we first evaluated the expression of VEGF in a mouse model of liver warm ischemia. We found that the expression of VEGF increased after ischemia but peaked between 2 and 6 hours after reperfusion. Mice were treated with a neutralizing anti-mouse VEGF antiserum (anti-VEGF) or control serum daily from day -1 (1 day before the initiation of ischemia). Treatment with anti-VEGF significantly reduced serum glutaminic pyruvic transaminase levels and reduced histological evidence of hepatocellular damage compared with controls. Anti-VEGF also markedly decreased T-cell, macrophage, and neutrophil accumulation within livers and reduced the frequency of intrahepatic apoptotic terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling-positive cells. Moreover, there was a reduction in the expression of pro-inflammatory cytokines (tumor necrosis factor-alpha and interferon-gamma), chemokines (interferon-inducible protein-10 and monocyte chemoattractant protein-1) and adhesion molecules (E-selectin) in parallel with enhanced expression of anti-apoptotic genes (Bcl-2/Bcl-xl and heme oxygenase-1) in anti-VEGF-treated animals. In conclusion, hypoxia-inducible VEGF expression by hepatocytes modulates leukocyte trafficking and leukocyte-induced injury in a mouse liver model of warm I/R injury, demonstrating the importance of endogenous VEGF production in the pathophysiology of hepatic I/R injury.     

Expression of vascular endothelial growth factor receptor Flk-1 in canine mammary tumours

Vascular endothelial growth factor (VEGF) induces endothelial cell proliferation, and the beginning of angiogenesis, by interacting with specific endothelial receptors termed VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1). In this study, Flk-1 expression was evaluated immunohistochemically in 10 benign and 40 malignant canine mammary tumours. There was immunolabelling of endothelial cells located within the neoplastic proliferation and at the infiltrating periphery, and also of neoplastic cells. The number of positive endothelial and neoplastic cells, was higher in malignant than in benign tumours. Moreover, in the malignant tumours, expression of Flk-1 increased from well to less differentiated phenotypes (grade 1-3). The presence of VEGF receptor on neoplastic cells suggests that VEGF has an autocrine function in which neoplastic cells act as both VEGF producers and target cells. Thus, in malignant tumours, VEGF may contribute to neoplastic growth by inducing angiogenesis and by stimulating the proliferation of neoplastic cells.     

大鼠脑缺血后血管内皮生长因子和血管生成素的表达变化及其作用

目的 探讨大鼠脑缺血后血管内皮生长因子(VEGF)和血管生成素(angiopoietin,Ang)的表达变化及其在血管生成和血管通透性变化中的作用.方法 选择160只雄性SD大鼠,采用随机区组法分为假手术组,缺血2h、6h、12h、1d、3d、7d和14d组,用线栓法制作大脑中动脉阻塞脑缺血损伤模型,分别于脑缺血后不同时间点处死大鼠.通过逆转录聚合酶链反应(RT-PCR)、Western blot及免疫组织化学方法检测大鼠脑缺血后不同时间点VEGF、Ang-1及Ang-2 mRNA和蛋白的表达变化.CD31标记鼠脑缺血后不同时间点的血管数量.Evans blue检测血脑屏障通透性.结果 大鼠脑缺血后VEGF mRNA表达逐渐增高,12 h达第一个高峰(0.7249 ±0.1933,P＜0.01),7d达第二个高峰(0.5264±0.1519,P＜0.01);VEGF蛋白表达也逐渐增高,于12 h达高峰(1.1017±0.1302,P＜0.01).Ang-2 mRNA和蛋白在脑缺血组织也逐渐增高,均12 h达高峰(0.6747±0.2416,P＜0.01;1.1197±0.1780,P＜0.01).与之相反,Ang-1 mRNA和蛋白表达逐渐降低,分别于3 d(0.3220±0.1427,P＜0.01)和1 d(0.1298±0.0293,P＜0.01)达最低水平,这些因子在脑缺血后的表达促进血管生成.脑缺血后血管通透性逐渐增加,EB含量在缺血1d达高峰[(6.219±0.887) μg/g,P＜0.01].结论 大鼠脑缺血后VEGF、Ang-1和Ang-2共同协调作用促进血管生成,在组织损伤修复过程中发挥着重要的作用.     

脑缺血再灌注模型大鼠跑台运动后海马神经再生和血管内皮生长因子mRNA的变化

背景：研究表明跑台运动能促进健康大鼠海马的神经细胞再生。 目的：观察跑台运动对脑缺血再灌注模型大鼠海马神经再生和血管内皮生长因子mRNA表达的影响。 方法：用线栓法阻塞大脑中动脉以建立单侧脑缺血再灌注模型大鼠,将建模成功大鼠随机分为跑台运动组和安静对照组,另设假手术组。安静对照组和假手术组大鼠安静饲养,跑台运动组进行7 d跑台运动。跑台运动组和安静对照组大鼠在每天跑台运动前腹腔注射5-溴脱氧尿嘧啶核苷溶液。 结果与结论：免疫组织化学染色结果显示,跑台运动组大鼠双侧海马及齿状回5-溴脱氧尿嘧啶核苷阳性表达细胞数量显著多于安静对照组(P < 0.01)。实时荧光定量PCR检测结果显示,跑台运动组大鼠海马血管内皮生长因子mRNA表达水平显著高于安静对照组和假手术组(P < 0.05)。结果证实,跑台运动能够明显促进脑缺血再灌注大鼠海马神经细胞的再生并上调海马组织血管内皮生长因子的表达。     

血管内皮生长因子及其受体在子宫内膜异位症中的表达和意义

目的:研究血管内皮生长因子(Vascular endothelial growth factor,VEGF)及其受体(Vascular endothelial growth factor receptor1,VEGFR1)在子宫内膜异位症(内异症)患者子宫在位内膜、异位内膜及正常对照组内膜组织中的表达,探讨其在子宫内膜异位症中的作用机制.方法:采用免疫组织化学及Western blot方法检测34例异位症患者在位内膜、异位内膜(内异症组)及34例正常内膜(对照组)组织中VEGF及其受体VEGFR1蛋白的定位及表达.结果:异症组在位及异位子宫内膜组织腺上皮细胞及间质细胞中均有VEGF及VEGFR1蛋白表达,且均高于同期对照组内膜,差异有统计学意义;对照组分泌期内膜VEGF及VEGFR1蛋白表达高于增生期,呈现周期性变化,而内异症组在位及异位内膜VEGF及VEGFR1蛋白表达失去周期性变化,分泌期与增生期均高表达,差异无统计学意义.Western blot检测结果与免疫组化结果一致.结论:内异症患者在位及异位内膜组织中VEGF、VEGFR1蛋白高表达可能与内异症的发生发展有关.     

Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma

The purpose of this study was to evaluate the association between the expression of growth factors and the clinicopathological variables of colorectal adenocarcinoma. Immunohistochemistry and fluorescence in situ hybridization (FISH) were used to evaluate the amplification and expression of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF-D, VEGF receptor (VEGFR)-2, VEGFR-3, transforming growth factor (TGF)-β1, and insulin-like growth factor-1 receptor (IGF-1R) in a tissue microarray of 292 colorectal adenocarcinomas. The expression of EGFR, VEGF, VEGF-D, VEGFR-2 and VEGFR-3 was detected in 5.1%, 10.0%, 6.8%, 5.2%, and 57.2%. EGFR expression was associated with angioinvasion (p < 0.05) and lymph node metastasis (p < 0.005). VEGFR-3 expression was higher in the rectum than in the colon (p < 0.05). VEGF expression correlated with VEGF-D (p < 0.05) and VEGFR-3 (p < 0.005) expression, while VEGF-D expression showed no significant association with VEGFR-2 or VEGFR-3. EGFR amplification was present in 10.6% and was not associated with EGFR protein expression. VEGFR-2 and VEGFR-3 expression levels were related to poor patient survival. Stage, perineural invasion, and lymph node metastasis were independent prognostic factors based on a Cox analysis. VEGFR-2 and VEGFR-3 expression are markers of a poor prognosis in patients with surgically resected colorectal adenocarcinoma, whereas EGFR has a minor influence.     

缺血/再灌注损伤时丝裂原活化蛋白激酶信号转导通路的变化

丝裂原活化蛋白激酶 (ｍｉｔｏｇｅｎ -ａｃｔｉｖａｔｅｄｐｒｏｔｅｉｎｋｉｎａｓｅｓ,ＭＡＰＫｓ)是一类丝 /苏氨酸蛋白激酶 ,是公认与细胞增殖、分化或凋亡调控密切相关的细胞内信号转导酶类 ,到目前为止 ,在哺乳类动物细胞中 ,已经发现ＭＡＰＫｓ家族具有ＥＲＫｓ(ｅｘｔｒａｃｅｌｌｕｌａｒｓｉｇｎａｌ-ｒｅｇｕｌａｔｅｄｋｉｎａｓｅｓ)、ＪＮＫｓ/ＳＡＰＫｓ(ｃ -ＪｕｎＮＨ2 -ｔｅｒ ｍｉｎａｌｋｉｎａｓｅｓ/ｓｔｒｅｓｓ -ａｃｔｉｖａｔｅｄｐｒｏｔｅｉｎｋｉｎａｓｅｓ)、ｐ38ＭＡＰＫ等不同亚类 ,其信号途径上游的信号…     

Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat

Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) promotes the repair of injured vessels by stimulating angiogenesis. VEGF/VPF reportedly has cytoprotective activity but no study has shown the protective effect of VEGF/VPF on glomerular endothelial cells. We examined whether recombinant VEGF/VPF121 and VEGF/VPF165 isoforms could prevent injury of glomerular endothelial cells. Mild glomerular injury was induced in rats by an intravenous-injection of a limited dose of anti-Thy-1.1 antibody to obtain lesions similar to those found in the human disease. Recombinant VEGF/VPF165, VEGF/VPF121 or BSA was administered 4 h before the injection of the antibody, and once daily for 3 days. In the BSA-injected rats, mesangial cell lysis and endothelial cell injury in dilated capillary tufts were evident without endothelial cell apoptosis on days 1-4. Thereafter, cell proliferation and repair began and remodeling of the glomeruli was completed by day 28. Macrophages but not polymorphonuclear leukocytes accumulated significantly in the glomeruli on days 1-4. Treatment with VEGF/VPF isoform protected endothelial cells but not mesangial cells from destruction on day 1, and accelerated the repair of both types of cells, which was completed by day 18, 10 days earlier than that of the control animals. The results indicate that VEGF/VPF121 or VEGF/VPF165 can protect glomerular endothelial cells against injury, independent of apoptosis-inhibition activity, thereby promoting reconstruction of glomeruli. The protective effect of VEGF/VPF on endothelial cells suggests that it could provide therapeutic benefit for certain kidney diseases.     

人血管内皮生长因子在毕赤酵母菌中的表达和鉴定

目的 研究人血管内皮生长因子（ｈＶＥＧＦ１６５）基因在Ｐｉｃｈｉａ．ｐａｓｔｏｒｉｓ酵母中的表达,获得高效表达的具有生物学活性的重组ＶＥＧＦ１６５。方法 采用聚合酶链反应（ＰＣＲ）扩增ｈＶＥＧＦ１６５基因,经ＤＮＡ序列分析后,插入含ＡＯＸ１启动子和α分泌信号肽序列的Ｐｉｃｈｉａ．ｐａｓｔｏｒｉｓ酵母载体中,构建重组表达质粒ｐＰＩＣ９Ｋ／ｈＶＥＧＦ１６５,转化酵母宿主菌ＫＭ７１,筛选多拷贝整合转化子,摇瓶培养,１％甲醇诱导表达。结果 ＳＤＳ－ＰＡＧＥ分析显示,诱导４ｄ的培养上清中ｈＶＥＧＦ１６５表达量达上清总蛋白的３０％以上。ＥＬＩＳＡ及Ｗｅｓｔｅｒｎ ｂｌｏｔ实验表明,表达产物具有良好的抗原性和特异性。生物学活性检测证实其具有刺激ＨＵＶＥＣ增殖的功能。结论 在Ｐｉｃｈｉａ．ｐａｓｔｏｒｉｓ表达系统中实现了ｈＶＥ     

血管内皮生长因子C及其受体3在人恶性黑色素瘤组织内的表达及意义

目的 观察人恶性黑色素瘤组织内血管内皮生长因子C(VEGF-C)及其受体3(VEGFR-3)的表达,探讨VEGF-C和VEGFR-3在恶性黑色素瘤淋巴管生成及淋巴道转移中的作用.方法 取人恶性黑色素瘤组织48例(石蜡标本30例,术后新鲜组织18例),应用免疫组织化学和RT-PCR技术,观察VEGF-C和VEGFR-3蛋白及mRNA在恶性黑色素瘤组织内的表达情况.以淋巴管内皮透明质酸受体(LYVE-1)标记淋巴管,计数恶性黑色素瘤组织淋巴管数密度.结果 VEGF-C和VEGFR-3蛋白主要表达于恶性黑色素瘤细胞胞浆内,在肿瘤周围的血管和淋巴管内皮上也可见VEGFR-3蛋白表达,VEGF-C和VEGFR-3蛋白在淋巴结转移组恶性黑色素瘤组织内的表达水平明显高于无淋巴结转移组(P<0.05).在18例新鲜恶性黑色素瘤中,淋巴结转移组VEGF-C和VEGFR-3mRNA的表达明显高于无淋巴结转移组(P<0.01).LYVE-1表达于肿瘤间质内的淋巴管内皮细胞,淋巴结转移组恶性黑色素瘤组织中的淋巴管数密度(LMVD)为9.845±2.454,无淋巴结转移组恶性黑色素瘤组织中的淋巴管数密度为6.534±2.193,淋巴结转移组恶性黑色素瘤组织内的淋巴管数密度明显高于无淋巴结转移组(P<0.01).结论恶性黑色素瘤组织内VEGF-C表达明显增高,并通过上调其受体VEGFR-3的表达促进恶性黑色素瘤组织内淋巴管的生成,从而促进恶性黑色素瘤的淋巴道转移.     

Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma

Vascular endothelial growth factor receptor 3 (VEGFR-3) has been proposed as a marker for lymphatic endothelial cells. This study investigated the expression of VEGFR-3 in the tumour vessels of lung adenocarcinoma and evaluated whether VEGFR-3 staining was useful for identifying lymphatic vessels within the tumour stroma. It also explored whether active growth of lymphatic vessels occurred in lung adenocarcinoma. Formalin-fixed, paraffin-embedded specimens obtained from 60 cases of lung adenocarcinoma, including five cases of pure bronchiolo-alveolar carcinoma (BAC) without stromal, vascular, and pleural invasion, were examined. No VEGFR-3-positive vessels were observed in pure BAC, but varying numbers of VEGFR-3-positive vessels were found in 39 of 55 (70.9%) invasive adenocarcinomas. A comparison of serial sections stained for VEGFR-3, CD31, and laminin-1 showed that most of the VEGFR-3-positive vessels appeared to be blood vessels (CD31-positive, laminin-1-positive), but some had the characteristics of lymphatic vessels (variable staining for CD31, little or no staining for laminin-1). VEGFR-3 staining highlighted lymphatic invasion by cancer cells; this invasion could not be detected by CD31 or haematoxylin and eosin (H&E) staining. Active growth of lymphatic vessels (as indicated by nuclear Ki-67 labelling of the endothelium) was observed in five tumours, four of which showed a high level of lymphatic invasion by cancer cells. It was concluded that VEGFR-3 immunostaining did not discriminate clearly between vascular and lymphatic endothelial cells, since expression of VEGFR-3 can be up-regulated in tumour blood vessels. However, VEGFR-3 staining combined with laminin-1 and CD31 staining would be useful for identifying lymphatic vessels and their invasion by tumour cells in a more objective way. Finally, proliferation of lymphatic endothelial cells may occur in association with lymphatic invasion by cancer cells.     

Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells

The advanced glycation end products (AGEs) are associated with increased cardiac endothelial injury. However, no causative link has been established between increased AGEs and enhanced endothelial injury after ischemia/reperfusion. More importantly, the molecular mechanisms by which AGEs may increase endothelial injury remain unknown. Adult rat cardiac microvascular endothelial cells (CMECs) were isolated and incubated with AGE-modified bovine serum albumin (BSA) or BSA. After AGE-BSA or BSA preculture, CMECs were subjected to simulated ischemia (SI)/reperfusion (R). AGE-BSA increased SI/R injury as evidenced by enhanced lactate dehydrogenase release and caspase-3 activity. Moreover, AGE-BSA significantly increased SI/R-induced oxidative/nitrative stress in CMECs (as measured by increased inducible nitric oxide synthase expression, total nitric oxide production, superoxide generation, and peroxynitrite formation) and increased SI/R-induced nitrative inactivation of thioredoxin-1 (Trx-1), an essential cytoprotective molecule. Supplementation of EUK134 (peroxynitrite decomposition catalyst), human Trx-1, or soluble receptor of advanced end product (sRAGE) (a RAGE decoy) in AGE-BSA precultured cells attenuated SI/R-induced oxidative/nitrative stress, reduced SI/R-induced Trx-1 nitration, preserved Trx-1 activity, and reduced SI/R injury. Our results demonstrated that AGEs may increase SI/R-induced endothelial injury by increasing oxidative/nitrative injury and subsequent nitrative inactivation of Trx-1. Interventions blocking RAGE signaling or restoring Trx activity may be novel therapies to mitigate endothelial ischemia/reperfusion injury in the diabetic population.     

Expression of vascular endothelial growth factor in renal cell carcinomas

Vascular endothelial growth factor (VEGF) is an angiogenic factor that may be involved in tumor growth and metastasis. Only a few data concerning the role of VEGF in renal cell carcinomas (RCCs) are available, and no studies have yet evaluated its prognostic value. The aim of the present study was to assess VEGF expression in a large series of renal tumors with a long follow-up, correlated with the usual histoprognostic factors and survival. VEGF immunostaining was performed on formalin-fixed, paraffin-embedded archival tissue from 74 renal carcinomas (62 conventional renal cell and 12 papillary carcinomas). Positivity of immunostaining was semi-quantitatively scored by two pathologists. Angiogenesis was evaluated by immunostaining with anti-CD34 antibodies on serial sections. Cytoplasmic VEGF expression was detected in tumor cells in 35% (26/74) of RCCs, including 18 out of the 62 (29%) conventional RCCs and 8 out of the 12 (67%) papillary carcinomas (P=0.02). In the group of conventional RCCs, VEGF expression was positively correlated with both nuclear grade (P=0.05) and size of the tumor (P=0.05). Furthermore, a significant correlation was observed between VEGF expression and microvascular count (P=0.04). Finally, cumulative survival rate was significantly lower in the group of patients with conventional RCCs expressing VEGF (log rank test, P=0.01). In the Cox model, VEGF expression was a significant independent predictor of outcome, as well as stage and nuclear grade. This study suggests that VEGF is involved in angiogenesis in conventional RCCs and appears to be a potential prognostic factor in these tumors. Received: 9 July 1999 / Accepted: 18 October 1999     

Expression of vascular endothelial growth factor in the dental follicle

Tooth eruption requires the presence of the dental follicle to recruit mononuclear cells, which fuse to form osteoclasts that resorb the alveolar bone such that the tooth can erupt. In the rat first mandibular molar, there is a major burst of osteoclastogenesis at day 3 postnatally and a lesser burst at day 10. Eruption molecules, such as CSF-1, are maximally expressed at day 3 in the dental follicle to promote this maximal osteoclast formation, but by the time of the secondary burst of osteoclastogenesis their expression is dramatically reduced. Because vascular endothelial growth factor (VEGF) can substitute for CSF-1 to promote osteoclastogenesis, we examined its gene expression in vivo in the dental follicle and found that it and its two major isoforms (VEGF 120 and 164) were all maximally expressed at days 9-11, the time of the secondary burst. Treatment of the cells with phorbolmyristate acetate (PMA), a protein kinase C (PKC) activator, enhanced expression of the 2 major VEGF isoforms in the cultured dental follicle cells, whereas adding a specific PKC inhibitor prevented this. Treatment with PMA also increased the protein level of VEGF. Thus, VEGF may be involved in promoting the secondary burst of osteoclastogenesis, and activation of PKC may upregulate its expression.